Case Reports in Endocrinology

Case Reports in Endocrinology / 2014 / Article

Case Report | Open Access

Volume 2014 |Article ID 423563 | 4 pages | https://doi.org/10.1155/2014/423563

A Case of Marine-Lenhart Syndrome with a Negative TSH Receptor Antibody Titer Successfully Treated with a Fixed, Low Dose of I131

Academic Editor: Thomas Grüning
Received11 Jun 2014
Accepted17 Jul 2014
Published03 Aug 2014

Abstract

We herein describe a case of Marine-Lenhart syndrome with a negative TSH receptor antibody titer. A 75-year-old female presented to our hospital with malaise, palpitations, and mild fine tremors. She did not have any signs suggestive of Graves’ ophthalmopathy, including conjunctival injection, periorbital edema, or proptosis. Her laboratory data were negative for thyroid autoantibodies, including anti-thyroid peroxidase antibodies, anti-thyroglobulin antibodies, and anti-TSH receptor antibodies (TRAb). Ultrasonography of the thyroid gland revealed a tumor in the right lobe. The remaining thyroid gland had an inhomogeneous and rough texture with a high color Doppler flow. I123 scintigraphy disclosed a hot nodule in the right thyroid gland corresponding to the tumor detected on ultrasonography, suggesting Plummer disease. Furthermore, there was an increased uptake of radionuclide in the rest of the thyroid gland, despite the suppressed level of TSH and negative titer of TRAb, suggesting underlying Graves’ disease. The present findings suggested a diagnosis of Marine-Lenhart syndrome with a negative TRAb titer. Treatment with 10 mCi of radioiodine was highly effective in treating hyperthyroidism in this case. A negative TSH receptor antibody titer does not necessarily rule out the existence of Graves’ disease in patients with Plummer disease.

1. Introduction

Thyrotoxicosis results from autonomic thyroid hyperfunction or destructive processes [1]. A representative thyroid autonomy (hyperthyroidism) is Graves’ disease, a common autoimmune disease caused by TSH receptor stimulating antibodies (TRAb) [1]. Hyperthyroidism also results from autonomic functioning adenomas (solitary toxic adenoma or Plummer disease) [1]. Marine-Lenhart syndrome is a rare disorder consisting of both Graves’ disease and Plummer disease [2]. There have been various case reports describing Marine-Lenhart syndrome; however, to the best of our knowledge, all previously reported cases except two cases involved a positive TRAb titer [24].

In this report, we describe a case of Marine-Lenhart syndrome with a negative TSH receptor antibody titer. Treatment with a fixed, low dose of radioiodine was highly effective for treating hyperthyroidism in this case. We also briefly review and discuss the treatment options for Marine-Lenhart syndrome.

2. Case Presentation

A 75-year-old female presented to our hospital with malaise, palpitations, and mild fine tremors. She had felt ambiguous chest discomfort for a long period of time. In addition, she was anxious about her unintentional weight loss. Her past medical history was unremarkable except for untreated hepatitis C virus infection. Mild hyperthyroidism had been detected; however, the accurate diagnosis was not confirmed for at least two years at another hospital. Her family history was negative for endocrinopathy, including thyroid disease. She was currently receiving treatment with amlodipine for hypertension and rivaroxaban for paroxysmal atrial fibrillation. She was thin and appeared tired on general inspection. On a physical examination, she was found to be 156 cm in height and 46 kg in weight (body mass index: 18.9 kg/m2). Her blood pressure was 140/80 mmHg and her heart rate was 104 beats per minute. No diffuse goiters were apparent on inspection, and no abnormal masses were palpable in the thyroid gland. She did not exhibit any signs suggestive of Graves’ ophthalmopathy, including conjunctival injection, periorbital edema, or proptosis.

The laboratory data were as follows: AST = 46 IU/L (range, 11–28), ALT = 54 IU/L (range, 7–23), ALP = 352 IU/L (range, 115–330), γGTP = 18 IU/L (range, 9–27), TSH = <0.005 μIU/mL (range, 0.2–4.0), free thyroxine = 2.66 ng/dL (range, 1.00–2.00), free triiodothyronine = 11.35 pg/mL (range, 2.30–4.00), and negative thyroid autoantibodies, including negative TRAb, negative anti-thyroglobulin antibodies (TGAb), and negative anti-thyroid peroxidase antibodies (TPOAb). Thyroid autoantibodies were tested twice, with negative results both times. TSH receptor stimulating antibodies (TSAb), as assessed on a bioassay, were also negative.

Ultrasonography of the thyroid gland revealed a tumor in the right lobe (Figure 1) measuring 21.5 mm × 19.4 mm × 36.3 mm in diameter. The lesion had a relatively low echoic appearance and sharp border. No areas of microcalcification were detected in the tumor, although areas of macrocalcification were present. The remaining thyroid gland had an inhomogeneous, rough texture with a high color Doppler flow (Figure 2). I123 scintigraphy was performed following iodine restriction for one week prior to the study, revealing a hot nodule in the lower right thyroid gland corresponding to the tumor detected on ultrasonography (Figure 3). The total uptake percentage of I123 for four hours was approximately 24% (range: 4–16%). Surprisingly, there was an increased uptake of radionuclide in the remaining thyroid gland despite the suppressed level of TSH and negative TRAb titer, suggesting underlying Graves’ disease.

Thioamides, which are commonly used to treat Graves’ disease in Japan, have the well-known side effect of hepatotoxicity [5, 6]. Because the patient displayed elevated liver enzymes due to her untreated hepatitis C, we administered 10 mCi of radioiodine instead of thioamides. After the treatment, her subjective ambiguous chest discomfort, possibly due to paroxysmal atrial fibrillation, was ameliorated. Thyroid function test results on a regular visit conducted one month after the radioiodine treatment were as follows: TSH = <0.005 μIU/mL (range, 0.2–4.0), free thyroxine = 1.40 ng/dL (range, 1.00–2.00), and free triiodothyronine = 4.91 pg/mL (range, 2.30–4.00). Her hyperthyroidism was successfully improved one month after the administration of the radioisotope and no episodes of recurrence have since been observed.

3. Discussion

In this case, the results of ultrasonography and I123 scintigraphy were compatible with a diagnosis of Marine-Lenhart syndrome. Marine-Lenhart syndrome is a rare disorder, with an incidence of 1~2.7% in patients with Graves’ disease [7, 8]. The currently available assay for TSH receptor antibodies has sufficiently high sensitivity and specificity [5]. There is a previous case report of Marine-Lenhart syndrome associated with a negative TRAb titer, positive TPO antibody titer, and positive TG antibody titer [3]. However, in that report, the ultrasonographic study showed no nodularity, as pointed out in a review by Biersack and Biermann [2]. In addition, Chatzopoulos et al. previously reported a case of Marine-Lenhart syndrome associated with a negative TRAb titer [4]. However, in this report, the TSH level was not fully suppressed and a Tc-99m scan showed a homogenously increased uptake throughout the thyroid gland before radioiodine treatment.

Since TRAb was negative in the present report, the diagnosis of Graves’ disease was made based on the detection of a homogenous radioiodine uptake in the extranodular thyroid tissue, despite the suppressed level of TSH and the hypervascularity of the extranodular thyroid gland on ultrasonography, as shown in Figure 2. In addition, the high free T3/free T4 ratio observed before treatment suggested the presence of underlying Graves’ disease. Although the definitive diagnosis should rely on the pathological findings of the thyroid tissue and we could not obtain histological findings supporting the definite diagnosis of Graves’ disease, to the best of our knowledge, we believe that the present report is the first case report of Marine-Lenhart syndrome with a negative TRAb titer showing compatible radiological findings.

The treatment options for Graves’ disease include thioamides, radioiodine, and surgery [5]. In Japan and Europe, thioamides are commonly used to treat Graves’ disease, while radioiodine is often utilized in the United States [5, 6]. Hepatotoxicity is a well-known side effect of thioamides [5]. Because our patient had a history of untreated hepatitis C and elevated liver enzymes, we treated her with radioiodine in order to avoid hepatotoxicity. In contrast to Graves’ disease, Plummer disease is often treated with surgery or radioiodine [5]. Thioamides are seldom used for the treatment for Plummer disease; these drugs are only applied in limited cases [5]. There is an observation that a higher dose of radioiodine is generally required for Marine-Lenhart syndrome due to the development of radioresistance [7]. In another case report, the dose of radioiodine was reported to be 20 mCi for the treatment for Marine-Lenhart syndrome and such a high dose of radioiodine has been reported to lead to the development of postablative hypothyroidism [9]. In contrast to these observations, we successfully treated our patient with a fixed, low dose of 10 mCi of I131 in the outpatient setting. Although the utilization of a low dose of I131 does not deny the possible occurrence of hypothyroidism in the future, the dose of 10 mCi was sufficiently enough for the treatment of our case. Because Marine-Lenhart syndrome consists of both Graves’ disease and Plummer disease, treatment with a relatively low dose of radioiodine is a reasonable first choice for ameliorating both disease etiologies simultaneously.

In conclusion, a negative TSH receptor antibody titer does not necessarily rule out the existence of Graves’ disease in patients with Plummer disease. The high free T3/free T4 ratio, ultrasonography, and thyroid scintigraphy are, thus, considered to be helpful for making a diagnosis in such cases. Marine-Lenhart syndrome can, therefore, be successfully managed with a relatively low, fixed dose of radioiodine.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

  1. J. A. Franklyn and K. Boelaert, “Thyrotoxicosis,” The Lancet, vol. 379, no. 9821, pp. 1155–1166, 2012. View at: Publisher Site | Google Scholar
  2. H. Biersack and K. Biermann, “The Marine-Lenhart syndrome revisited,” Wiener Klinische Wochenschrift, vol. 123, no. 15-16, pp. 459–462, 2011. View at: Publisher Site | Google Scholar
  3. S. El-Kaissi, M. A. Kotowicz, M. Goodear, and J. R. Wall, “An unusual case of Marine-Lenhart syndrome,” Thyroid, vol. 13, no. 10, pp. 993–994, 2003. View at: Publisher Site | Google Scholar
  4. D. Chatzopoulos, I. Iakovou, and E. Moralidis, “Marine-Lenhart syndrome and radioiodine-131 treatment,” Thyroid, vol. 17, no. 4, pp. 373–374, 2007. View at: Publisher Site | Google Scholar
  5. R. S. Bahn, H. B. Burch, D. S. Cooper et al., “Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,” Thyroid, vol. 21, no. 6, pp. 593–646, 2011. View at: Publisher Site | Google Scholar
  6. S. Yamashita, N. Amino, and Y. K. Shong, “The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines: viewpoints from Japan and Korea,” Thyroid, vol. 21, no. 6, pp. 577–580, 2011. View at: Publisher Site | Google Scholar
  7. N. D. Charkes, “Graves' disease with functioning nodules (Marine-Lenhart syndrome).,” Journal of Nuclear Medicine, vol. 13, no. 12, pp. 885–892, 1972. View at: Google Scholar
  8. N. E. Carnell and W. A. Valente, “Thyroid nodules in Graves' disease: classification, characterization, and response to treatment,” Thyroid, vol. 8, pp. 647–652, 1998. View at: Google Scholar
  9. M. Braga-Basaría and S. Basaria, “Marine-Lenhart Syndrome,” Thyroid, vol. 13, no. 10, p. 991, 2003. View at: Publisher Site | Google Scholar

Copyright © 2014 Masahiro Takei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1582 Views | 463 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.